Chronic bronchitis is clinically defined as the presence of a productive cough (with sputum) for at least 3 months per year, for two consecutive years, in the absence of any other pulmonary or cardiac cause that could explain these symptoms. It results from persistent inflammation of the bronchi, leading to excessive mucus secretion, enlargement of the mucous glands, and a progressive impairment of mucociliary clearance. Chronic bronchitis is one of the two major components of COPD (chronic obstructive pulmonary disease)—along with emphysema—a generic term referring to a group of obstructive lung diseases characterized by a not entirely reversible obstruction of airflow. COPD is the third leading cause of death worldwide (WHO). Specialized medical care is essential for any patient with chronic bronchitis—consult a pulmonologist for a comprehensive initial evaluation, including spirometry.
Smoking accounts for 80 to 90 percent of COPD cases: smoke destroys the bronchial cilia, impairs the mucosal immune response, and perpetuates chronic local inflammation. Other contributing factors include air pollution (fine particulate matter PM2.5), prolonged occupational exposure (mineral dust, isocyanates, cadmium), and severe recurrent respiratory infections during childhood. Call 15 in case of acute respiratory distress, cyanosis, or altered consciousness.
Symptoms develop gradually over the course of years before the patient seeks medical care: a productive morning cough (the characteristic “morning sputum”), progressive shortness of breath on exertion, wheezing, increasingly frequent and severe winter respiratory infections, and chronic fatigue. Shortness of breath on exertion is often the first sign that prompts a visit to the doctor—at this stage, the loss of lung function is already significant.
The diagnosis is based on spirometry (the gold standard test)—which measures FEV1 (forced expiratory volume in one second) and the FEV1/FVC ratio. An FEV₁/FVC ratio < 0.70 after bronchodilation confirms the irreversible bronchial obstruction characteristic of COPD. The GOLD classification (I–IV) grades severity based on FEV₁ and guides treatment decisions. Chest X-rays and lung CT scans rule out differential diagnoses (bronchial cancer, pneumonia, asthma). Sputum analysis identifies pathogens during exacerbations.
There is no curative treatment for chronic bronchitis—management aims to slow progression, reduce exacerbations, and improve quality of life.Smoking cessation is the only intervention that significantly alters the natural history of the disease—it immediately slows the rate of FEV1 decline. Medications include inhaled bronchodilators (beta-2 agonists, anticholinergics) to reduce airway obstruction, inhaled corticosteroids for frequent exacerbations, and antibiotics during documented infectious exacerbations. Annual influenza and pneumococcal vaccinations are recommended for all patients with COPD.
To support medical treatment, several natural approaches contribute to daily management. English ivy (bronchospasm-relieving and expectorant saponins—well-established use by the EMA) helps thin and clear mucus. Adequate hydration (1.5 to 2 L/day) is essential for maintaining the fluidity of bronchial secretions. Vitamin C (an antioxidant that protects bronchial epithelial cells from oxidative stress caused by smoke and pollution) and vitamin D3 (which reduces the frequency of infectious exacerbations) are supported by clinical evidence in favor of supplementation in COPD patients with deficiencies. Propolis supports the immunity of the respiratory mucosa between infectious episodes. Chronicbronchial congestion warrants regular respiratory physical therapy. These approaches are not a substitute for pulmonological follow-up and prescribed medical treatment.
